Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Trastuzumab With FLOT in Perioperative Treatment of HER2-positive Localized Esophagogastric Adenocarcinoma
NCT05504720Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, trastuzumab in Esophago-Gastric Adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT05504720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504720.